Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
EGFR positive
i
Other names:
EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
1956
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Associations
(8)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer (NCT04024462)
Phase 3
Hoffmann-La Roche
Hoffmann-La Roche
Active, not recruiting
Phase 3
Hoffmann-La Roche
Active, not recruiting
Last update posted :
06/12/2024
Initiation :
02/05/2020
Primary completion :
12/13/2021
Completion :
11/11/2025
PIK3CA
|
HER-2 positive • HER-2 amplification • PIK3CA mutation • EGFR positive
|
Herceptin (trastuzumab) • docetaxel • tamoxifen • doxorubicin hydrochloride • cyclophosphamide • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) • cyclophosphamide intravenous
Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (KEYNOTE-603) (NCT03313778)
Phase 1
ModernaTX, Inc.
ModernaTX, Inc.
Recruiting
Phase 1
ModernaTX, Inc.
Recruiting
Last update posted :
06/04/2024
Initiation :
08/14/2017
Primary completion :
06/30/2025
Completion :
06/30/2025
EGFR • ALK • TMB
|
EGFR mutation • ALK positive • ALK translocation • EGFR positive
|
Keytruda (pembrolizumab) • mRNA-4157 • pembrolizumab subcutaneous (MK-3475 SC)
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer (NCT03742245)
Phase 1
The Methodist Hospital Research Institute
The Methodist Hospital Research Institute
Recruiting
Phase 1
The Methodist Hospital Research Institute
Recruiting
Last update posted :
06/03/2024
Initiation :
06/11/2019
Primary completion :
09/01/2025
Completion :
03/01/2026
HER-2
|
EGFR positive
|
Lynparza (olaparib) • Zolinza (vorinostat)
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer (EMBER) (NCT04188548)
Phase 1
Eli Lilly and Company
Eli Lilly and Company
Active, not recruiting
Phase 1
Eli Lilly and Company
Active, not recruiting
Last update posted :
05/30/2024
Initiation :
12/10/2019
Primary completion :
06/29/2020
Completion :
12/01/2027
ER
|
HER-2 negative • EGFR positive
|
Herceptin (trastuzumab) • everolimus • Perjeta (pertuzumab) • Piqray (alpelisib) • Verzenio (abemaciclib) • exemestane • imlunestrant (LY3484356)
Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer (NCT05954871)
Phase 1
Genentech, Inc.
Genentech, Inc.
Recruiting
Phase 1
Genentech, Inc.
Recruiting
Last update posted :
05/29/2024
Initiation :
01/08/2024
Primary completion :
12/31/2026
Completion :
12/31/2026
KRAS • BRAF • NRAS
|
BRAF V600E • EGFR mutation • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • EGFR positive
|
Erbitux (cetuximab) • Tagrisso (osimertinib) • migoprotafib (RLY-1971)
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) (NCT05296798)
Phase 3
Hoffmann-La Roche
Hoffmann-La Roche
Recruiting
Phase 3
Hoffmann-La Roche
Recruiting
Last update posted :
05/28/2024
Initiation :
07/04/2022
Primary completion :
08/31/2026
Completion :
09/30/2032
HER-2 • ER
|
ER positive • EGFR positive
|
paclitaxel • docetaxel • tamoxifen • Perjeta (pertuzumab) • giredestrant (GDC-9545) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (CHRYSALIS) (NCT02609776)
Phase 1
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Active, not recruiting
Phase 1
Janssen Research & Development, LLC
Active, not recruiting
Last update posted :
05/22/2024
Initiation :
05/24/2016
Primary completion :
01/31/2024
Completion :
06/30/2025
ALK • MET
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR exon 20 insertion • EGFR wild-type • MET exon 14 mutation • EGFR C797S • MET mutation • MET expression • EGFR exon 20 mutation • EGFR positive
|
carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy (Astefania) (NCT04873362)
Phase 3
Hoffmann-La Roche
Hoffmann-La Roche
Recruiting
Phase 3
Hoffmann-La Roche
Recruiting
Last update posted :
05/15/2024
Initiation :
05/04/2021
Primary completion :
06/25/2026
Completion :
06/29/2035
HER-2 • PD-L1
|
EGFR positive
|
Herceptin (trastuzumab) • Tecentriq (atezolizumab) • Kadcyla (ado-trastuzumab emtansine)
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA) (NCT03175224)
Phase 2
Apollomics Inc.
Apollomics Inc.
Recruiting
Phase 2
Apollomics Inc.
Recruiting
Last update posted :
05/10/2024
Initiation :
09/27/2017
Primary completion :
03/30/2026
Completion :
11/30/2026
HGF • PTPRZ1
|
EGFR mutation • MET amplification • EGFR wild-type • MET exon 14 mutation • MET overexpression • MET expression • EGFR positive • MET fusion
|
bozitinib (APL-101) • CBT101
Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02) (NCT05101096)
Phase 1/2
Gilead Sciences
Gilead Sciences
Recruiting
Phase 1/2
Gilead Sciences
Recruiting
Last update posted :
05/10/2024
Initiation :
10/20/2021
Primary completion :
05/01/2026
Completion :
05/01/2026
HER-2
|
HR positive • HER-2 negative • EGFR positive
|
Trodelvy (sacituzumab govitecan-hziy)
A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer (ProHer) (NCT05415215)
Phase 3
Hoffmann-La Roche
Hoffmann-La Roche
Active, not recruiting
Phase 3
Hoffmann-La Roche
Active, not recruiting
Last update posted :
04/16/2024
Initiation :
07/05/2022
Primary completion :
03/31/2025
Completion :
12/31/2025
HER-2
|
HER-2 amplification • EGFR positive
|
Herceptin (trastuzumab) • carboplatin • paclitaxel • docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • cyclophosphamide • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver (NCT02273362)
Phase 1/2
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Completed
Phase 1/2
National Cancer Institute (NCI)
Completed
Last update posted :
03/26/2024
Initiation :
11/24/2014
Primary completion :
02/11/2020
Completion :
03/10/2022
EGFR • EGF • PCNA
|
EGFR positive
|
erlotinib
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (NCT02057133)
Phase 1
Eli Lilly and Company
Eli Lilly and Company
Active, not recruiting
Phase 1
Eli Lilly and Company
Active, not recruiting
Last update posted :
03/25/2024
Initiation :
03/10/2014
Primary completion :
03/15/2021
Completion :
12/31/2024
HER-2 • CDK4 • CDK6
|
HR positive • HER-2 negative • EGFR positive
|
Herceptin (trastuzumab) • everolimus • tamoxifen • Perjeta (pertuzumab) • Verzenio (abemaciclib) • fulvestrant • letrozole • anastrozole • exemestane • samotolisib (LY3023414) • loperamide
A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD) (NCT04834778)
Phase 1
HiberCell, Inc.
HiberCell, Inc.
Completed
Phase 1
HiberCell, Inc.
Completed
Last update posted :
03/08/2024
Initiation :
06/08/2021
Primary completion :
12/07/2023
Completion :
01/30/2024
HER-2
|
EGFR positive
|
HC-5404
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E) (NCT04585477)
Phase 2
Stanford University
Stanford University
Recruiting
Phase 2
Stanford University
Recruiting
Last update posted :
02/26/2024
Initiation :
04/08/2021
Primary completion :
04/01/2024
Completion :
04/01/2026
PD-L1 • ALK • ROS1
|
PD-L1 expression • EGFR mutation • PD-L1 overexpression • EGFR L858R • EGFR exon 19 deletion • EGFR expression • ALK rearrangement • ROS1 rearrangement • EGFR positive
|
Imfinzi (durvalumab)
SMMART Adaptive Clinical Treatment (ACT) Trial (NCT05238831)
Phase 1
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
Withdrawn
Phase 1
OHSU Knight Cancer Institute
Withdrawn
Last update posted :
01/23/2024
Initiation :
01/30/2023
Primary completion :
05/31/2026
Completion :
05/31/2026
HER-2 • BRCA1 • BRCA2
|
BRCA2 mutation • BRCA1 mutation • HR positive • HER-2 negative • EGFR positive
|
Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • carboplatin • Rozlytrek (entrectinib) • Alecensa (alectinib) • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • capecitabine • Piqray (alpelisib) • Zejula (niraparib) • albumin-bound paclitaxel • fulvestrant • irinotecan • Halaven (eribulin mesylate) • letrozole • vinorelbine tartrate • Herzuma (trastuzumab-pkrb) • anastrozole • Erivedge (vismodegib) • Trazimera (trastuzumab-qyyp) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • EG1206A (pertuzumab biosimilar)
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer (TBCRC 050) (NCT03368729)
Phase 1/2
University of Alabama at Birmingham
University of Alabama at Birmingham
Recruiting
Phase 1/2
University of Alabama at Birmingham
Recruiting
Last update posted :
01/01/2024
Initiation :
09/06/2019
Primary completion :
11/01/2024
Completion :
12/30/2024
PGR
|
ER positive + PGR positive • PGR positive • EGFR positive
|
Herceptin (trastuzumab) • Zejula (niraparib)
Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC:Prospective Study (SELECT-2) (NCT04401059)
Phase 4
Tian Xie
Tian Xie
Recruiting
Phase 4
Tian Xie
Recruiting
Last update posted :
12/27/2023
Initiation :
11/09/2020
Primary completion :
09/30/2025
Completion :
03/30/2026
EGFR • ALK • TP53 • MSI • PTEN • STK11 • JAK2 • PBRM1 • JAK1 • MDM4 • POLD1
|
EGFR mutation • EGFR L858R • EGFR positive
|
Tagrisso (osimertinib) • erlotinib • gefitinib • Conmana (icotinib) • Ameile (aumolertinib) • Ivesa (firmonertinib)
Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study (ROSE) (NCT05089916)
Phase 2
AIO-Studien-gGmbH
AIO-Studien-gGmbH
Recruiting
Phase 2
AIO-Studien-gGmbH
Recruiting
Last update posted :
12/25/2023
Initiation :
01/20/2022
Primary completion :
12/01/2025
Completion :
12/01/2026
EGFR
|
EGFR mutation • EGFR T790M • EGFR positive
|
Tagrisso (osimertinib)
Optimizing Treatment of Stage IV Breast Cancer Through Real-Time Disease Monitoring (NCT04906369)
Phase N/A
Mayo Clinic
Mayo Clinic
Suspended
Phase N/A
Mayo Clinic
Suspended
Last update posted :
12/25/2023
Initiation :
11/16/2020
Primary completion :
11/15/2024
Completion :
11/15/2024
HER-2 • ER
|
ER positive • EGFR positive
The Postoperative Radiotherapy in N1 Breast Cancer Patients (PORT-N1) (NCT05440149)
Phase 3
Seoul National University Hospital
Seoul National University Hospital
Recruiting
Phase 3
Seoul National University Hospital
Recruiting
Last update posted :
11/24/2023
Initiation :
08/01/2022
Primary completion :
12/31/2026
Completion :
12/31/2033
HER-2
|
HR positive • EGFR positive
A Post Marketing Surveillance on Piqray in Korea (NCT05293470)
Phase N/A
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Recruiting
Phase N/A
Novartis Pharmaceuticals
Recruiting
Last update posted :
11/21/2023
Initiation :
06/29/2022
Primary completion :
05/12/2027
Completion :
05/12/2027
HER-2 • PIK3CA
|
EGFR mutation • HR positive • HER-2 negative • PIK3CA mutation • EGFR positive
|
Piqray (alpelisib)
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer (TROPiCS-02) (NCT03901339)
Phase 3
Gilead Sciences
Gilead Sciences
Completed
Phase 3
Gilead Sciences
Completed
Last update posted :
11/20/2023
Initiation :
05/08/2019
Primary completion :
10/20/2023
Completion :
10/20/2023
HER-2
|
HR positive • HER-2 negative • EGFR positive
|
gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Trodelvy (sacituzumab govitecan-hziy)
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies (NCT01325441)
Phase 1/2
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc.
Completed
Phase 1/2
Sumitomo Pharma America, Inc.
Completed
Last update posted :
11/15/2023
Initiation :
04/01/2011
Primary completion :
06/01/2021
Completion :
06/01/2021
BRAF • ER • ALK • PGR
|
HER-2 positive • BRAF V600E • HER-2 negative • BRAF V600 • ALK positive • BRAF V600K • BRAF wild-type • ER negative • EGFR positive • PGR negative
|
paclitaxel • albumin-bound paclitaxel • napabucasin (BBI608)
Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NCT05673590)
Phase 3
Beijing Biostar Pharmaceuticals Co., Ltd.
Beijing Biostar Pharmaceuticals Co., Ltd.
Recruiting
Phase 3
Beijing Biostar Pharmaceuticals Co., Ltd.
Recruiting
Last update posted :
11/08/2023
Initiation :
05/12/2023
Primary completion :
06/15/2025
Completion :
12/31/2025
ALK
|
EGFR mutation • ALK positive • EGFR T790M • ALK fusion • EGFR positive
|
docetaxel • utidelone IV (UTD1)
EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors (NCT03638167)
Phase 1
Seattle Children's Hospital
Seattle Children's Hospital
Active, not recruiting
Phase 1
Seattle Children's Hospital
Active, not recruiting
Last update posted :
10/27/2023
Initiation :
03/19/2019
Primary completion :
03/01/2025
Completion :
03/01/2040
EGFR
|
EGFR expression • EGFR positive
|
EGFR806-specific CAR T-cell therapy
Real-life Pan-HER-blockade With Neratinib (ELEANOR) (NCT04388384)
Phase N/A
Pierre Fabre Pharma GmbH
Pierre Fabre Pharma GmbH
Active, not recruiting
Phase N/A
Pierre Fabre Pharma GmbH
Active, not recruiting
Last update posted :
10/24/2023
Initiation :
07/02/2020
Primary completion :
01/01/2025
Completion :
01/01/2025
HER-2
|
HR positive • HER-2 overexpression • HER-2 amplification • EGFR positive
|
Nerlynx (neratinib)
Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France (NCT02307812)
Phase N/A
Eli Lilly and Company
Eli Lilly and Company
No Longer Available
Phase N/A
Eli Lilly and Company
No Longer Available
Last update posted :
10/20/2023
HER-2
|
EGFR positive
|
cisplatin • paclitaxel • Cyramza (ramucirumab)
Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer (4CAST) (NCT04947189)
Phase 1b
St Vincent's Hospital, Sydney
St Vincent's Hospital, Sydney
Recruiting
Phase 1b
St Vincent's Hospital, Sydney
Recruiting
Last update posted :
10/16/2023
Initiation :
11/01/2022
Primary completion :
07/01/2024
Completion :
12/01/2024
HER-2 • PGR • AR
|
HR positive • HER-2 negative • AR positive • EGFR positive
|
docetaxel • dexamethasone • seviteronel (INO-464)
Real World Study of Biosimilar Trastuzumab in Her2 Positive Breast Cancer (LB1802) (NCT03892655)
Phase N/A
Libbs Farmacêutica LTDA
Libbs Farmacêutica LTDA
Active, not recruiting
Phase N/A
Libbs Farmacêutica LTDA
Active, not recruiting
Last update posted :
10/12/2023
Initiation :
10/07/2019
Primary completion :
12/30/2022
Completion :
07/01/2028
HER-2
|
EGFR positive
|
Ogivri (trastuzumab-dkst)
Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients (NCT06071013)
Phase 2
China Medical University Hospital
China Medical University Hospital
Not yet recruiting
Phase 2
China Medical University Hospital
Not yet recruiting
Last update posted :
10/06/2023
Initiation :
09/28/2023
Primary completion :
08/27/2026
Completion :
08/27/2026
EGFR
|
EGFR mutation • EGFR positive
|
erlotinib • Gilotrif (afatinib) • gefitinib • nintedanib
Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins (IMAGE-II) (NCT02965755)
Phase N/A
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Cent...
Active, not recruiting
Phase N/A
Sidney Kimmel Comprehensive Cancer Center at Jo...
Active, not recruiting
Last update posted :
10/06/2023
Initiation :
01/26/2018
Primary completion :
07/01/2024
Completion :
07/01/2024
HER-2
|
HR positive • EGFR positive
Early On-treatment Transcriptional Profiling as Predictor of Response in Early-stage HER2-positive Breast Cancer (BiOnHER) (NCT05912062)
Phase N/A
Institut Català d'Oncologia
Institut Català d'Oncologia
Recruiting
Phase N/A
Institut Català d'Oncologia
Recruiting
Last update posted :
09/29/2023
Initiation :
03/22/2021
Primary completion :
06/01/2024
Completion :
12/01/2024
HER-2 • ER • PGR
|
HER-2 positive • EGFR positive
|
Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab)
Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02) (NCT05328440)
Phase 2
Henan Cancer Hospital
Henan Cancer Hospital
Recruiting
Phase 2
Henan Cancer Hospital
Recruiting
Last update posted :
09/25/2023
Initiation :
05/20/2022
Primary completion :
06/01/2024
Completion :
01/01/2026
HER-2 • ER • PGR
|
ER negative • EGFR positive
|
Herceptin (trastuzumab) • Irene (pyrotinib) • fulvestrant • AiRuiKang (dalpiciclib) • Cipterbin (inetetamab)
A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody (NCT06048315)
Phase 3
Degan Lu
Degan Lu
Not yet recruiting
Phase 3
Degan Lu
Not yet recruiting
Last update posted :
09/21/2023
Initiation :
09/01/2023
Primary completion :
06/01/2026
Completion :
09/01/2026
EGFR • BRAF
|
EGFR mutation • EGFR positive
|
paclitaxel • Focus V (anlotinib) • Anniko (penpulimab)
A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors (NCT06043466)
Phase 1
Chongqing Precision Biotech Co., Ltd
Chongqing Precision Biotech Co., Ltd
Recruiting
Phase 1
Chongqing Precision Biotech Co., Ltd
Recruiting
Last update posted :
09/21/2023
Initiation :
08/11/2023
Primary completion :
12/31/2026
Completion :
12/31/2027
PD-L1 • BRAF • ALK • ROS1 • NTRK
|
PD-L1 expression • HER-2 positive • EGFR mutation • HR positive • ALK positive • EGFR T790M • ALK fusion • EGFR positive • CEACAM5 positive
|
cyclophosphamide • C-13-60
Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers (NCT05109442)
Phase 1/2
Affimed GmbH
Affimed GmbH
Recruiting
Phase 1/2
Affimed GmbH
Recruiting
Last update posted :
08/29/2023
Initiation :
11/19/2021
Primary completion :
09/30/2024
Completion :
06/30/2025
EGFR
|
EGFR mutation • EGFR T790M • EGFR wild-type • EGFR positive
|
Tecentriq (atezolizumab) • AFM24
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login